We observed that CD56neg CD16+ NK cells from AML patients down-regulated CCR1 and CCR5, involved in NK cell recruitment in inflamed tissues, and up-regulated CCL3 and CCL4, known as CCR5 ligands. This evidence concerns the gene CCL4 and acute myeloid leukemia.